Prognostic and Diagnostic Kits and Herbal Therapies for Treating Skin Conditions, Autoimmune Diseases, Inflammatory Ailments and Cancer

A method of treating scalp psoriasis, dermatitis, atopic dermatitis, eczema, herpes, shingles, rheumatoid arthritis (RA), arthritic psoriasis/psoriatic arthritis, Alzheimer's, Parkinson's, irritable bowel syndrome (MS), colitis, prostitis, vasculitis, osteoarthritis, seborrheic dermatitis, acne, colitis, skin lesions, diabetes, hypertension, allergies, asthma, capuche sarcoma, autoimmune, inflammation, dermatologic, cardiovascular, metabolic syndrome, hypotension, coronary artery disease, depression, lupus, sarcoidosis, muscular sclerosis, crohn's disease, UV exposure, burns, warts, dandruff, seborrheic dandruff, chronic inflammation, seborrhea, keratosis, alopecia, hirsutism, capitis, melanoma or non-melanoma skin cancer, basal cell cancer (BCC), squamous cell cancer (SCC), scleroderma, dermatofibrosarcoma protuberans, Merkel cell carcinoma, Kaposi's sarcoma, keratoacanthoma, spindle cell tumors, sebaceous carcinomas, microcystic adnexal carcinoma, Paget's disease of the breast, atypical fibroxanthoma, leiomyosarcoma, and angiosarcoma, Marjolin's ulcers, kidney failure, nerve damage caused by a skin condition, or skin burrowing mites, or a skin ailment, lesion or sore, particularly of the scalp and also for other skin regions affected by an ailment that is susceptible to topical or hair treatment, as well as hair fall or hair loss conditions, or combinations thereof, comprising:

• measuring a level or combination of levels of one or more of IL-5, IL-13, IL-17, IL-23, TNF-α, IL-6, IL-7, IL-13, GMCSF, MCP-1, IL-9, IL-1-β, IL-1-RA, IL-8, IL-9, IL-10, IL-12, IL-19, IL-20, IL-22, IL-24, IL-26, eotaxin, FGF-β, G-CSF, IFN-γ, IP-10, MIP-1, PDGFRB, MIP-1-β, RANTES, VEGF, JAK, JAK1, JAK3, MPO (myeloperoxidase), p38kinase, BRAF, BRAF V599E, KRAS, EGFR, ALK, TRPV1, TRPA1, MRGPRA3, PAR2, mucunain or other proteases, chloroquine, pruritogen, cowhage, sapsaicin, ROS, RET. SK-Mel-2, HT-29, MCF-7, THP-1, DU-145, MOLT-4, THP-1, K562, HL-60, U937, PD-1, ICAM-1, VCAM-1, E-selectin, HACAT-THP-1, LYN, ABL, BTK, SYK, ZAP-70, PI3KCD, AKT, HER-2, FLT-3, KIT, LCK, MAPK1, MEK1, PGE, PGE2, PGE2-E4, MMP, PI3K-δ, PIK3CD, PIK3R1 CCL3, CCL4, PLC, BCR, CD-5, CD-38, CD-19, CD-20, CD-79a, β2M, NO, LTB4, PLA2, or PDE4, ORA KINASE, E.G., AKT1 (PKB ALPHA), ERBB2 (HER2), FLT3, MAPK1 (ERK2), PRKCA (PKC ALPHA), BRAF, BRAF V599E OR MAP2K1 (MEK1), or combinations thereof, in a first bodily fluid, serum or skin sample, or both, extracted from a patient;
• formulating a diagnosis of scalp psoriasis, dermatitis, atopic dermatitis, eczema, herpes, shingles, rheumatoid arthritis (RA), arthritic psoriasis/psoriatic arthritis, Alzheimer's, Parkinson's, irritable bowel syndrome (IBS), colitis, prostitis, vasculitis, osteoarthritis, seborrheic dermatitis, acne, colitis, skin lesions, diabetes, hypertension, allergies, asthma, capuche sarcoma, autoimmune, inflammation, dermatologic, cardiovascular, metabolic syndrome, hypotension, coronary artery disease, depression, lupus, sarcoidosis, muscular sclerosis, crohn's disease, UV exposure, burns, warts, dandruff, seborrheic dandruff, chronic inflammation, seborrhea, keratosis, alopecia, hirsutism, capitis, melanoma or non-melanoma skin cancer, basal cell cancer (BCC), squamous cell cancer (SCC), scleroderma, dermatofibrosarcoma protuberans, Merkel cell carcinoma, Kaposi's sarcoma, keratoacanthoma, spindle cell tumors, sebaceous carcinomas, microcystic adnexal carcinoma, Paget's disease of the breast, atypical fibroxanthoma, leiomyosarcoma, and angiosarcoma, Marjolin's ulcers, kidney failure, nerve damage caused by a skin condition, or skin burrowing mites, or a skin ailment, lesion or sore, particularly of the scalp and also for other skin regions affected by an ailment that is susceptible to topical or hair treatment, as well as hair fall or hair loss conditions, or combinations thereof, for the patient based on said measured level or combination of levels and on one or more expected correlations between said level or combination of levels and manifestation within said patient of one or more diseases;
• and
• administering a medicinal composition that comprises an effective dose between 1.0 wt. %-15 wt. % of an herbal combination of Da Huang, Sheng Di Huang and Jin Yin Hua for a 50 kg patient or 2-12 grams for a 100 kg patient to treat the patient in accordance with said diagnosis.

A medicine for treating scalp psoriasis, dermatitis, atopic dermatitis, eczema, herpes, shingles, rheumatoid arthritis (RA), arthritic psoriasis/psoriatic arthritis, Alzheimer's, Parkinson's, irritable bowel syndrome (MS), colitis, prostitis, vasculitis, osteoarthritis, seborrheic dermatitis, acne, colitis, skin lesions, diabetes, hypertension, allergies, asthma, capuche sarcoma, autoimmune, inflammation, dermatologic, cardiovascular, metabolic syndrome, hypotension, coronary artery disease, depression, lupus, sarcoidosis, muscular sclerosis, crohn's disease, UV exposure, burns, warts, dandruff, seborrheic dandruff, chronic inflammation, seborrhea, keratosis, alopecia, hirsutism, capitis, melanoma or non-melanoma skin cancer, basal cell cancer (BCC), squamous cell cancer (SCC), scleroderma, dermatofibrosarcoma protuberans, Merkel cell carcinoma, Kaposi's sarcoma, keratoacanthoma, spindle cell tumors, sebaceous carcinomas, microcystic adnexal carcinoma, Paget's disease of the breast, atypical fibroxanthoma, leiomyosarcoma, and angiosarcoma, Marjolin's ulcers, kidney failure, nerve damage caused by a skin condition, or skin burrowing mites, or a skin ailment, lesion or sore, particularly of the scalp and also for other skin regions affected by an ailment that is susceptible to topical or hair treatment, as well as hair fall or hair loss conditions, or combinations thereof, comprising:

• a shampoo, conditioner, cream, lotion, ointment or other topical skin, scalp or hair treatment or a pill, skin patch, gel, injection pen, subdermal injection, IV fluid, tablet, capsule, lipid carrier, nano-crystal or other nano-particulate formulation, subcutaneous insert, or stent, or combinations thereof, that comprises a predetermined number of one or more effective doses, each effective dose including between 20-160 mg/kg of an herbal combination of Da Huang, Sheng Di Huang and Jin Yin Hua.

A medicine for treating scalp psoriasis, dermatitis, atopic dermatitis, eczema, herpes, shingles, rheumatoid arthritis (RA), arthritic psoriasis/psoriatic arthritis, Alzheimer's, Parkinson's, irritable bowel syndrome (IBS), colitis, prostitis, vasculitis, osteoarthritis, seborrheic dermatitis, acne, colitis, skin lesions, diabetes, hypertension, allergies, asthma, capuche sarcoma, autoimmune, inflammation, dermatologic, cardiovascular, metabolic syndrome, hypotension, coronary artery disease, depression, lupus, sarcoidosis, muscular sclerosis, crohn's disease, UV exposure, burns, warts, dandruff, seborrheic dandruff, chronic inflammation, seborrhea, keratosis, alopecia, hirsutism, capitis, melanoma or non-melanoma skin cancer, basal cell cancer (BCC), squamous cell cancer (SCC), scleroderma, dermatofibrosarcoma protuberans, Merkel cell carcinoma, Kaposi's sarcoma, keratoacanthoma, spindle cell tumors, sebaceous carcinomas, microcystic adnexal carcinoma, Paget's disease of the breast, atypical fibroxanthoma, leiomyosarcoma, and angiosarcoma, Marjolin's ulcers, kidney failure, nerve damage caused by a skin condition, or skin burrowing mites, or a skin ailment, lesion or sore, particularly of the scalp and also for other skin regions affected by an ailment that is susceptible to topical or hair treatment, as well as hair fall or hair loss conditions, or combinations thereof, comprising

• a shampoo, conditioner, cream, lotion, ointment or other topical skin, scalp or hair treatment or a pill, skin patch, gel, injection pen, subdermal injection, IV fluid, tablet, capsule, lipid carrier, nano-crystal or other nano-particulate formulation, subcutaneous insert, or stent, or combinations thereof, that comprises a predetermined number of one or more effective doses, each effective dose including between 1.0 wt. %-15.0 wt. % of said herbal combination of Da Huang, Sheng Di Huang and Jin Yin Hua.

A medical kit, comprising:

• a diagnostic kit, including a test kit and an indicator, said test kit for measuring a level or combination of levels of one or more of IL-5, IL-13, IL-17, IL-23, TNF-α, IL-6, IL-7, IL-13, GMCSF, MCP-1, IL-9, IL-113, IL-1-RA, IL-8, IL-9, IL-10, IL-12, IL-19, IL-20, IL-22, IL-24, IL-26, eotaxin, FGF-β, G-CSF, IFN-γ, IP-10, MIP-1, PDGFRB, MIP-1-β, RANTES, VEGF, JAK, JAK1, JAK3, MPO (myeloperoxidase), p38kinase, BRAF, BRAF V599E, KRAS, EGFR, ALK, TRPV1, TRPA1, MRGPRA3, PAR2, mucunain or other proteases, chloroquine, pruritogen, cowhage, sapsaicin, ROS, RET. SK-Mel-2, HT-29, MCF-7, THP-1, DU-145, MOLT-4, THP-1, K562, HL-60, U937, PD-1, ICAM-1, VCAM-1, E-selectin, HACAT-THP-1, LYN, ABL, BTK, SYK, ZAP-70, PI3KCD, AKT, HER-2, FLT-3, KIT, LCK, MAPK1, MEK1, PGE, PGE2, PGE2-E4,MMP, PI3K-δ, PIK3CD, PIK3R1 CCL3, CCL4, PLC, BCR, CD-5, CD-38, CD-19, CD-20, CD-79a, β2M, NO, LTB4, PLA2, or PDE4, OR A KINASE, E.G., AKT1 (PKB ALPHA), ERBB2 (HER2), FLT3, MAPK1 (ERK2), PRKCA (PKC ALPHA), BRAF, BRAF V599E OR MAP2K1 (MEK1), or combinations thereof, in a bodily fluid, serum or skin sample, or both, and said indicator for providing a diagnostic result based on said measured level or combinations of levels and on one or more expected correlations between said level or combination of levels and manifestation of one or more diseases including scalp psoriasis, dermatitis, atopic dermatitis, eczema, herpes, shingles, rheumatoid arthritis (RA), arthritic psoriasis/psoriatic arthritis, Alzheimer's, Parkinson's, irritable bowel syndrome (IBS), colitis, prostitis, vasculitis, osteoarthritis, seborrheic dermatitis, acne, colitis, skin lesions, diabetes, hypertension, allergies, asthma, capuche sarcoma, autoimmune, inflammation, dermatologic, cardiovascular, metabolic syndrome, hypotension, coronary artery disease, depression, lupus, sarcoidosis, muscular sclerosis, crohn's disease, UV exposure, burns, warts, dandruff, seborrheic dandruff, chronic inflammation, seborrhea, keratosis, alopecia, hirsutism, capitis, melanoma or non-melanoma skin cancer, basal cell cancer (BCC), squamous cell cancer (SCC), scleroderma, dermatofibrosarcoma protuberans, Merkel cell carcinoma, Kaposi's sarcoma, keratoacanthoma, spindle cell tumors, sebaceous carcinomas, microcystic adnexal carcinoma, Paget's disease of the breast, atypical fibroxanthoma, leiomyosarcoma, and angiosarcoma, Marjolin's ulcers, kidney failure, nerve damage caused by a skin condition, or skin burrowing mites, or a skin ailment, lesion or sore, particularly of the scalp and also for other skin regions affected by an ailment that is susceptible to topical or hair treatment, as well as hair fall or hair loss conditions, or combinations thereof;
• and
• a medicinal formulation comprising shampoo, conditioner, cream, lotion, ointment or other topical skin, scalp or hair treatment or a pill, skin patch, gel, injection pen, subdermal injection packet, IV fluid package, tablet, capsule, lipid carrier, nano-crystal or other nano-particulate formulation, subcutaneous insert, or stent, or combinations thereof, said medicinal formulation comprising a predetermined number of one or more effective doses, each effective dose including between 20-160 mg/kg of an herbal combination of Da Huang, Sheng Di Huang and Jin Yin Hua.

A medical kit, comprising:

• a diagnostic kit, including a test kit and an indicator, said test kit for measuring a level or combination of levels of one or more of IL-5, IL-13, IL-17, IL-23, TNF-α, IL-6, IL-7, IL-13, GMCSF, MCP-1, IL-9, IL-1-β, IL-1-RA, IL-8, IL-9, IL-10, IL-12, IL-19, IL-20, IL-22, IL-24, IL-26, eotaxin, FGF-β, G-CSF, IFN-γ, IP-10, MIP-1, PDGFRB, MIP-1β, RANTES, VEGF, JAK, JAK1, JAK3, MPO (myeloperoxidase), p38kinase, BRAF, BRAF V599E, KRAS, EGFR, ALK, TRPV1, TRPA1, MRGPRA3, PAR2, mucunain or other proteases, chloroquine, pruritogen, cowhage, sapsaicin, ROS, RET. SK-Me1-2, HT-29, MCF-7, THP-1, DU-145, MOLT-4, THP-1, K562, HL-60, U937, PD-1, ICAM-1, VCAM-1, E-selectin, HACAT-THP-1, LYN, ABL, BTK, SYK, ZAP-70, PI3KCD, AKT, HER-2, FLT-3, KIT, LCK, MAPK1, MEK1, PGE, PGE2, PGE2-E4, MMP, PI3K-δ, PIK3CD, PIK3R1 CCL3, CCL4, PLC, BCR, CD-5, CD-38, CD-19, CD-20, CD-79a, β2M, NO, LTB4, PLA2, or PDE4, OR A KINASE, E.G., AKT1 (PKB ALPHA), ERBB2 (HER2), FLT3, MAPK1 (ERK2), PRKCA (PKC ALPHA), BRAF, BRAF V599E OR MAP2K1 (MEK1), or combinations thereof, in a bodily fluid, serum or skin sample, or both, and said indicator for providing a diagnostic result based on said measured level or combinations of levels and on one or more expected correlations between said level or combination of levels and manifestation of one or more diseases including scalp psoriasis, dermatitis, atopic dermatitis, eczema, herpes, shingles, rheumatoid arthritis (RA), arthritic psoriasis/psoriatic arthritis, Alzheimer's, Parkinson's, irritable bowel syndrome (MS), colitis, prostitis, vasculitis, osteoarthritis, seborrheic dermatitis, acne, colitis, skin lesions, diabetes, hypertension, allergies, asthma, capuche sarcoma, autoimmune, inflammation, dermatologic, cardiovascular, metabolic syndrome, hypotension, coronary artery disease, depression, lupus, sarcoidosis, muscular sclerosis, crohn's disease, UV exposure, burns, warts, dandruff, seborrheic dandruff, chronic inflammation, seborrhea, keratosis, alopecia, hirsutism, capitis, melanoma or non-melanoma skin cancer, basal cell cancer (BCC), squamous cell cancer (SCC), scleroderma, dermatofibrosarcoma protuberans, Merkel cell carcinoma, Kaposi's sarcoma, keratoacanthoma, spindle cell tumors, sebaceous carcinomas, microcystic adnexal carcinoma, Paget's disease of the breast, atypical fibroxanthoma, leiomyosarcoma, and angiosarcoma, Marjolin's ulcers, kidney failure, nerve damage caused by a skin condition, or skin burrowing mites, or a skin ailment, lesion or sore, particularly of the scalp and also for other skin regions affected by an ailment that is susceptible to topical or hair treatment, as well as hair fall or hair loss conditions, or combinations thereof;
• and
• a medicinal formulation comprising shampoo, conditioner, cream, lotion, ointment or other topical skin, scalp or hair treatment or a pill, skin patch, gel, injection pen, subdermal injection packet, IV fluid package, tablet, capsule, lipid carrier, nano-crystal or other nano-particulate formulation, subcutaneous insert, or stent, or combinations thereof, said medicinal formulation comprising a predetermined number of one or more effective doses, each effective dose including between 1.0 wt. %-15 wt. % of an herbal combination of Da Huang, Sheng di Huang and Jin Yin Hua.

A prognostic kit, comprising:

• a medicinal formulation comprising shampoo, conditioner, cream, lotion, ointment or other topical skin, scalp or hair treatment or a pill, skin patch, gel, injection pen, subdermal injection packet, IV fluid package, tablet, capsule, lipid carrier, nano-crystal or other nano-particulate formulation, subcutaneous insert, or stent, or combinations thereof, said medicinal formulation comprising a predetermined number of one or more effective doses, each effective dose including between 20-160 mg/kg of an herbal combination of Da Huang, Sheng Di Huang and Jin Yin Hua, and
• a prognostic test kit for measuring a level or combination of levels of one or more of IL-5, IL-13, IL-17, IL-23, TNF-α, IL-6, IL-7, IL-13, GMCSF, MCP-1, IL-9, IL-1-β, IL-1-RA, IL-8, IL-9, IL-10, IL-12, IL-19, IL-20, IL-22, IL-24, IL-26, eotaxin, FGF-β, G-CSF, IFN-65 , IP-10, MIP-1, PDGFRB, MIP-1-β, RANTES, VEGF, JAK, JAK1, JAK3, MPO (myeloperoxidase), p38kinase, BRAF, BRAF V599E, KRAS, EGFR, ALK, TRPV1, TRPA1, MRGPRA3, PAR2, mucunain or other proteases, chloroquine, pruritogen, cowhage, sapsaicin, ROS, RET. SK-Mel-2, HT-29, MCF-7, THP-1, DU-145, MOLT-4, THP-1, K562, HL-60, U937, PD-1, ICAM-1, VCAM-1, E-selectin, HACAT-THP-1, LYN, ABL, BTK, SYK, ZAP-70, PI3KCD, AKT, HER-2, FLT-3, KIT, LCK, MAPK1, MEK1, PGE, PGE2, PGE2-E4, MMP, PI3K-δ, PIK3CD, PIK3R1 CCL3, CCL4, PLC, BCR, CD-5, CD-38, CD-19, CD-20, CD-79a, β2M, NO, LTB4, PLA2, or PDE4, OR A KINASE, E.G., AKT1 (PKB ALPHA), ERBB2 (HER2), FLT3, MAPK1 (ERK2), PRKCA (PKC ALPHA), BRAF, BRAF V599E OR MAP2K1 (MEK1), or combinations thereof, in first and second bodily fluid, serum or skin samples, or both, respectively extracted from a patient before and after a prognostic period of treatment with said medicinal formulation, and a prognostic indicator for providing a prognostic result for the patient based on a comparison of said measured level or combination of levels in the first and second bodily fluid, serum or skin samples, or both.

A prognostic kit, comprising:

• a shampoo, conditioner, cream, lotion, ointment or other topical skin, scalp or hair treatment or a pill, skin patch, gel, injection pen, subdermal injection, IV fluid, tablet, capsule, lipid carrier, nano-crystal or other nano-particulate formulation, subcutaneous insert, or stent, or combinations thereof, that comprises a predetermined number of one or more effective doses, each effective dose including between 1.0 wt. %-15.0 wt. % of an herbal combination of Da Huang, Sheng Di Huang and Jin Yin Hua;
• and
• a prognostic test kit for measuring a level or combination of levels of one or more of IL-5, IL-13, IL-17, IL-23, TNF-α, IL-6, IL-7, IL-13, GMCSF, MCP-1, IL-9, IL-1-β, IL-1-RA, IL-8, IL-9, IL-10, IL-12, IL-19, IL-20, IL-22, IL-24, IL-26, eotaxin, FGF-β, G-CSF, IFN-γ, IP-10, MIP-1, PDGFRB, MIP-1-β, RANTES, VEGF, JAK, JAK1, JAK3, MPO (myeloperoxidase), p38kinase, BRAF, BRAF V599E, KRAS, EGFR, ALK, TRPV1, TRPA1, MRGPRA3, PAR2, mucunain or other proteases, chloroquine, pruritogen, cowhage, sapsaicin, ROS, RET. SK-Mel-2, HT-29, MCF-7, THP-1, DU-145, MOLT-4, THP-1, K562, HL-60, U937, PD-1, ICAM-1, VCAM-1, E-selectin, HACAT-THP-1, LYN, ABL, BTK, SYK, ZAP-70, PI3KCD, AKT, HER-2, FLT-3, KIT, LCK, MAPK1, MEK1, PGE, PGE2, PGE2-E4, MMP, PI3K-δ, PIK3CD, PIK3R1 CCL3, CCL4, PLC, BCR, CD-5, CD-38, CD-19, CD-20, CD-79a, β2M, NO, LTB4, PLA2, or PDE4, or a kinase, e.g., AKT1 (PKB alpha), ERBB2 (HER2), FLT3, MAPK1 (ERK2), PRKCA (PKC alpha), BRAF, BRAF V599E or MAP2K1 (MEK1), or combinations thereof, in first and second bodily fluid, serum or skin samples, or both, respectively extracted from a patient before and after a prognostic period of treatment with said medicinal formulation, and a prognostic indicator for providing a prognostic result for the patient based on a comparison of measured levels or combinations of levels from said first and second bodily fluid, serum or skin samples, or both.